CD274 and Langerhans cell histiocytosis: As the role of the PD-L1 blockade in LCH biology is being currently tested, it is quite likely that these revised immune-related RECIST (iRECIST) and immune-related PERCIST (iPERCIST) guidelines may also need to be validated for the treatment response assessment in LCH patients as well [69, 70].